Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-21-026493
Filing Date
2021-05-14
Accepted
2021-05-14 17:00:39
Documents
45
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0321_actiniumpharma.htm 10-Q 609197
2 CERTIFICATION f10q0321ex31-1_actinium.htm EX-31.1 10021
3 CERTIFICATION f10q0321ex31-2_actinium.htm EX-31.2 10679
4 CERTIFICATION f10q0321ex32-1_actinium.htm EX-32.1 6001
5 CERTIFICATION f10q0321ex32-2_actinium.htm EX-32.2 4360
  Complete submission text file 0001213900-21-026493.txt   2396628

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE atnm-20210331.xml EX-101.INS 285513
7 XBRL SCHEMA FILE atnm-20210331.xsd EX-101.SCH 29859
8 XBRL CALCULATION FILE atnm-20210331_cal.xml EX-101.CAL 21371
9 XBRL DEFINITION FILE atnm-20210331_def.xml EX-101.DEF 124831
10 XBRL LABEL FILE atnm-20210331_lab.xml EX-101.LAB 260428
11 XBRL PRESENTATION FILE atnm-20210331_pre.xml EX-101.PRE 137143
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36374 | Film No.: 21925717
SIC: 2834 Pharmaceutical Preparations